KALA BIO Appoints Avi Minkowitz as New CEO and CFO Amidst Ongoing Financial Challenges
KALA is trading near its 52-week low of $0.38 (7.1% above the low) on light trading volume (0.1× avg).
Summary
KALA BIO, Inc. announced the resignation of its CEO and CFO, David Lazar, and the immediate appointment of Avi Minkowitz to both roles, signaling a leadership change during a critical period for the company.
Key Events · Executive and Board Changes · KALA
-
CEO and CFO Resignation
David Lazar resigned from his roles as Chief Executive Officer and Chief Financial Officer, effective February 2, 2026. He will remain a director on the Board.
-
New CEO and CFO Appointed
Avi Minkowitz, a current director, was appointed as the new Chief Executive Officer and Chief Financial Officer, effective February 2, 2026.
-
New Executive's Relevant Experience
Mr. Minkowitz brings experience in financing for publicly traded companies, M&A, business development, and management consulting focused on growth, restructuring, and financing, which is highly relevant given KALA BIO's recent challenges.
-
Context of Leadership Change
This executive transition occurs shortly after KALA BIO secured highly dilutive financing and received shareholder approval for a reverse stock split, following a Nasdaq non-compliance notice regarding its minimum bid price.
Analysis · KALA · Life Sciences
KALA BIO, a company facing significant financial distress and Nasdaq compliance issues, has replaced its Chief Executive Officer and Chief Financial Officer. The appointment of Avi Minkowitz, who has experience in financing, M&A, and restructuring, suggests a strategic move to address the company's precarious situation. This leadership change follows a series of highly dilutive financing activities and a Nasdaq non-compliance notice, indicating the board's intent to navigate the company through its current challenges. Investors will be watching to see if this new leadership can stabilize the company and improve its financial standing.
At the time of this filing, KALA was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1M. The 52-week trading range was $0.38 to $20.60. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.